Clemastine

CHEMBL1626 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
343.9 g/mol
LogP
5.0
Phase
4

An antihistamine that blocks H1 receptors to relieve allergy symptoms such as itching, hives, and runny nose. It is taken by mouth and may cause drowsiness due to its ability to cross into the brain.

الوزن الجزيئي

343,9000 g/mol

LogP

5,00

TPSA

12,50 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

آلية العمل

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1

InChI

InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1

Molecular Formula

C21H26ClNO

HBD / HBA

- / 2

الروابط القابلة للدوران

6

الذرات الثقيلة

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An antihistamine that blocks H1 receptors to relieve allergy symptoms such as itching, hives, and runny nose. It is taken by mouth and may cause drowsiness due to its ability to cross into the brain.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Clemastine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1626. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 26987. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.